查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1451768

2024-2032 年失智症藥物市場（依適應症、藥物類別、配銷通路和地區分類）

Dementia Drugs Market by Indication, Drug Class, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3個工作天內

價格

2023年全球失智症藥物市場規模達183億美元。展望未來， IMARC Group預計到2032年市場規模將達到346億美元，2024-2032年複合年成長率（CAGR）為7.09%。由於全球人口老化、人們對失智症相關疾病的認知和診斷不斷提高，以及為發現阿茲海默症和其他形式失智症的有效治療方法而進行的持續研究和開發工作，該市場正在經歷穩定成長。

失智症藥物市場分析：

市場成長與規模：在失智症相關疾病（尤其是阿茲海默症）盛行率不斷上升的推動下，全球失智症藥物市場正在經歷顯著成長。由於全球人口老化以及對控制認知能力下降和改善患者生活品質的有效治療的需求不斷成長，市場規模正在擴大。

技術進步：神經影像技術、生物標記識別和精準醫學的進步有助於早期診斷和個人化治療計劃。遠距醫療和數位健康平台正在加強對失智症患者和照護者的遠端監控和支援。

產業應用：癡呆藥物市場主要集中在藥品上，包括膽鹼酯酶抑制劑和NMDA受體拮抗劑。非藥物介入措施，例如認知刺激療法和行為管理策略，也變得越來越重要。

地理趨勢：由於失智症盛行率較高且研究基礎設施強大，北美和歐洲擁有完善的市場。由於意識的增強和醫療保健投資的增加，亞太地區的新興市場正在經歷快速成長。

競爭格局：市場的特點是競爭激烈，主要參與者專注於創新、併購（M&A）以及擴大全球足跡。製藥公司也在研發方面投入大量資金，以獲得競爭優勢。

挑戰與機會：挑戰包括藥物開發的高成本、監管障礙以及長期臨床試驗的需要。機會在於早期診斷、新藥發現和非藥物介入。

未來展望：失智症藥物市場可望持續成長，重點在於疾病緩解療法和個人化醫療。神經影像學、生物標記識別和遠距醫療的進步預計將塑造失智症護理的未來。

失智症藥物市場趨勢：

人口老化

失智症藥物市場的主要驅動力之一是全球人口老化。隨著人們壽命的延長，失智症等與年齡相關的疾病的發生率自然會增加。這種人口結構的變化導致對失智症相關醫療保健服務和藥物的需求增加。世界衛生組織報告稱，到2050年，60歲及以上的人口數量預計將增加一倍。老年人口的增加很可能導致失智症患病率激增，從而刺激對有效的失智症藥物的需求。

技術進步

失智症藥物市場也受到藥物研究和開發的重大進步的推動。隨著對失智症背後的神經生物學機制有了更好的了解，製藥公司擴大投資開發更有效、更有針對性的藥物。這些進展包括探索新的治療標靶，例如澱粉樣蛋白斑塊和 tau 蛋白，它們被認為在阿茲海默症（最常見的失智症）的發展中發揮著至關重要的作用。此外，神經影像技術的進步，例如正子斷層掃描（PET）和磁振造影（MRI），可以更準確地診斷和監測失智症相關疾病。此外，生物標記識別和基因研究正在推動精準醫學方法的發展。藥物發現、臨床試驗設計和遠距醫療的技術創新也提高了失智症藥物開發和病患照護的效率。

提高認知和早期診斷

人們對失智症及其症狀的認知不斷增強，從而促進了早期診斷和治療。公共衛生運動和教育措施正在提高人們對失智症早期症狀的認知，鼓勵人們儘早尋求醫療建議。早期診斷對於有效管理失智症至關重要，因為它可以及時干預並減緩疾病的進展。這種意識的不斷增強，加上診斷技術的改進，正在推動對失智症藥物的需求。

醫療保健支出增加

全球醫療保健支出的增加是推動失智症藥物市場的另一個因素。政府和醫療機構正在分配更多資源來管理和治療慢性病，包括失智症。增加的資金支持研究、藥物開發和改善治療選擇。它也反映出對加強醫療基礎設施和服務的更廣泛承諾，從而促進更好地管理失智症症狀和進展。此外，政府、醫療保健組織和倡導團體越來越認知到解決失智症的緊迫性。這種認可正在推動研究資金的成長，並創造有利於製藥創新的環境。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球癡呆藥物市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依跡象

  • 路易氏體失智症
    • 市場走向
    • 市場預測
  • 帕金森氏症 失智症
    • 市場走向
    • 市場預測
  • 阿茲海默氏症
    • 市場走向
    • 市場預測
  • 血管性失智症
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依藥物類別

  • 膽鹼酯酶抑制劑
    • 市場走向
    • 市場預測
  • NMDA拮抗劑及其組合藥物
    • 市場走向
    • 市場預測

第 8 章：市場區隔：按配銷通路

  • 零售藥局
    • 市場走向
    • 市場預測
  • 醫院藥房
    • 市場走向
    • 市場預測
  • 網路藥局
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：促進因素、限制與機會

  • 概述
  • 促進要素
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbvie Inc.
    • Apotex Inc.
    • Biogen Inc.
    • Eisai Co. Ltd.
    • Johnson & Johnson
    • Merck & Co. Inc.
Product Code: SR112024A7490

The global dementia drugs market reached US$ 18.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 34.6 Billion by 2032, exhibiting a growth rate (CAGR) of 7.09% during 2024-2032. The market is experiencing steady growth driven by aging global population, increasing awareness and diagnosis of dementia-related conditions, and ongoing research and development efforts to discover effective treatments for Alzheimer's disease and other forms of dementia.

Dementia Drugs Market Analysis:

Market Growth and Size: The global dementia drugs market is experiencing significant growth, driven by the increasing prevalence of dementia-related conditions, particularly Alzheimer's disease. Market size is expanding due to the aging global population and the rising demand for effective treatments to manage cognitive decline and improve the quality of life for patients.

Technological Advancements: Advances in neuroimaging technologies, biomarker identification, and precision medicine are aiding in early diagnosis and personalized treatment plans. Telemedicine and digital health platforms are enhancing remote monitoring and support for dementia patients and caregivers.

Industry Applications: The dementia drugs market is primarily focused on pharmaceuticals, including cholinesterase inhibitors and NMDA receptor antagonists. Non-pharmacological interventions, such as cognitive stimulation therapies and behavioral management strategies, are also gaining importance.

Geographical Trends: North America and Europe have well-established markets due to a higher prevalence of dementia and strong research infrastructure. Emerging markets in Asia-Pacific are experiencing rapid growth due to increasing awareness and healthcare investments.

Competitive Landscape: The market is characterized by intense competition with key players focusing on innovation, mergers and acquisitions (M&A), and expanding their global footprint. Pharmaceutical companies are also investing heavily in research and development to gain a competitive edge.

Challenges and Opportunities: Challenges include the high cost of drug development, regulatory hurdles, and the need for long-term clinical trials. Opportunities lie in early diagnosis, novel drug discovery, and non-pharmacological interventions.

Future Outlook: The dementia drugs market is poised for continued growth with a focus on disease-modifying therapies and personalized medicine. Advances in neuroimaging, biomarker identification, and telemedicine are expected to shape the future of dementia care.

Dementia Drugs Market Trends:

Ageing population

One of the primary drivers of the dementia drugs market is the aging global population. As people live longer, the incidence of age-related diseases like dementia naturally increases. This demographic shift results in a higher demand for dementia-related healthcare services and medications. The World Health Organization reports that the number of people aged 60 years and older is expected to double by 2050. This increase in the elderly population is likely to lead to a surge in the prevalence of dementia, thereby fueling the demand for effective dementia drugs.

Technological Advancements

The dementia drugs market is also driven by significant advancements in pharmaceutical research and development. With a better understanding of the neurobiological mechanisms behind dementia, pharmaceutical companies are increasingly investing in the development of more effective and targeted drugs. These advancements include the exploration of new therapeutic targets, such as amyloid plaques and tau proteins, which are believed to play a crucial role in the development of Alzheimer's disease, the most common form of dementia. Besides, advances in neuroimaging technologies, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), enable more accurate diagnosis and monitoring of dementia-related conditions. Additionally, biomarker identification and genetic research are driving the development of precision medicine approaches. Technological innovations in drug discovery, clinical trial design, and telemedicine are also enhancing the efficiency of dementia drug development and patient care.

Increasing awareness and early diagnosis

There is a growing awareness about dementia and its symptoms, leading to earlier diagnosis and treatment. Public health campaigns and educational initiatives are increasing awareness of dementia's early signs, encouraging people to seek medical advice sooner. Early diagnosis is crucial in managing dementia effectively, as it allows for timely intervention and slows the progression of the disease. This growing awareness, coupled with improvements in diagnostic techniques, is driving the demand for dementia drugs.

Rising healthcare expenditure

Increasing healthcare expenditure globally is another factor boosting the dementia drugs market. Governments and healthcare organizations are allocating more resources to manage and treat chronic conditions, including dementia. This increased funding supports research, drug development, and improved access to treatment options. It also reflects a broader commitment to enhancing healthcare infrastructure and services, thereby facilitating better management of dementia symptoms and progression. Besides, governments, healthcare organizations, and advocacy groups are increasingly recognizing the urgency of addressing dementia. This recognition is driving funding for research and creating an environment conducive to pharmaceutical innovation.

Dementia Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on indication, drug class, and distribution channel.

Breakup by Indication:

Lewy Body Dementia

Parkinson's Disease Dementia

Alzheimer's Disease

Vascular Dementia

Others

Alzheimer's disease accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the dementia drugs market based on the indication. This includes Lewy body dementia, Parkinson's disease dementia, Alzheimer's disease, vascular dementia, and others. According to the report, Alzheimer's disease represented the largest segment.

Breakup by Drug Class:

Cholinesterase Inhibitors

NMDA Antagonists and its Combination Drugs

Cholinesterase inhibitors holds the largest share in the industry

A detailed breakup and analysis of the dementia drugs market based on the drug class has also been provided in the report. This includes cholinesterase inhibitors and NMDA antagonists and its combination drugs. According to the report, cholinesterase inhibitors accounted for the largest market share.

Breakup by Distribution Channel:

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

Hospital pharmacies represents the leading market segment

The report has provided a detailed breakup and analysis of the dementia drugs market based on the distribution channel. This includes retail pharmacies, hospital pharmacies, and online pharmacies. According to the report, hospital pharmacies represented the largest segment.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest dementia drugs market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbvie Inc.

Apotex Inc.

Biogen Inc.

Eisai Co. Ltd.

Johnson & Johnson

Merck & Co. Inc.

Key Questions Answered in This Report:

  • How has the global dementia drugs market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global dementia drugs market?
  • What is the impact of each driver, restraint, and opportunity on the global dementia drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive dementia drugs market?
  • What is the breakup of the market based on the indication?
  • Which is the most attractive indication in the dementia drugs market?
  • What is the breakup of the market based on the drug class?
  • Which is the most attractive drug class in the dementia drugs market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the dementia drugs market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global dementia drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Dementia Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Indication

  • 6.1 Lewy Body Dementia
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Parkinson's Disease Dementia
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alzheimer's Disease
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Vascular Dementia
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Cholinesterase Inhibitors
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 NMDA Antagonists and its Combination Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Retail Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Hospital Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbvie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Apotex Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Biogen Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eisai Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Johnson & Johnson
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Dementia Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Dementia Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Dementia Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Dementia Drugs Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Dementia Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 6: Global: Dementia Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Dementia Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Dementia Drugs (Lewy Body Dementia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Dementia Drugs (Lewy Body Dementia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Dementia Drugs (Parkinson's Disease Dementia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Dementia Drugs (Parkinson's Disease Dementia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Dementia Drugs (Alzheimer's Disease) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Dementia Drugs (Alzheimer's Disease) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Dementia Drugs (Vascular Dementia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Dementia Drugs (Vascular Dementia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Dementia Drugs (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Dementia Drugs (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Dementia Drugs (Cholinesterase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Dementia Drugs (Cholinesterase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Dementia Drugs (NMDA Antagonists and its Combination Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Dementia Drugs (NMDA Antagonists and its Combination Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Dementia Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Dementia Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Dementia Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Dementia Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Dementia Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Dementia Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Dementia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Dementia Drugs Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Dementia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Dementia Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Dementia Drugs Industry: Value Chain Analysis
  • Figure 79: Global: Dementia Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Dementia Drugs Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Dementia Drugs Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 3: Global: Dementia Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 4: Global: Dementia Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Dementia Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Dementia Drugs Market: Competitive Structure
  • Table 7: Global: Dementia Drugs Market: Key Players